Content deleted Content added
Updating report |
Updating report |
||
Line 1:
{{User:SDZeroBot/NPP sorting/header|count=13|date=11 August 2025|ts=
{| class="wikitable sortable"
Line 62:
| [[177 Lu-NNS309]] <small>(Investigational radiopharmaceutical compound)</small>
| <sup>177</sup>Lu-NNS309 is an investigational radiopharmaceutical compound currently under development by Novartis Pharmaceuticals for the treatment of various [[Neoplasm|solid tumors]]. The compound is being evaluated in Phase I clinical trials for patients with pancreatic, lung, breast, and colorectal cancers.
| C▼
| data-sort-value=5566 | [[Special:Contribs/Noxoug1|Noxoug1]] (5566)▼
| ▼
|-▼
| 2025-07-29▼
| [[OpRegen]] <small>(Allogeneic cell therapy)</small>▼
| OpRegen (also known as RG6501) is an investigational allogeneic cell therapy developed by Lineage Cell Therapeutics for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The therapy consists of human retinal pigment epithelial (RPE) cells administered via subretinal injection as a single treatment.▼
| C
| data-sort-value=5566 | [[Special:Contribs/Noxoug1|Noxoug1]] (5566)
Line 99 ⟶ 92:
| Start
| data-sort-value=2568 | [[Special:Contribs/Mahmoudalrawi|Mahmoudalrawi]] (2568)
▲|
▲|-
▲| 2025-07-29
▲| [[OpRegen]] <small>(Allogeneic cell therapy)</small>
▲| OpRegen (also known as RG6501) is an investigational allogeneic cell therapy developed by Lineage Cell Therapeutics for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The therapy consists of human retinal pigment epithelial (RPE) cells administered via subretinal injection as a single treatment.
▲| C
▲| data-sort-value=5566 | [[Special:Contribs/Noxoug1|Noxoug1]] (5566)
|
|}
<span style="font-style: italic; font-size: 85%;">Last updated by [[User:SDZeroBot|SDZeroBot]] <sup>''[[User:SD0001|operator]] / [[User talk:SD0001|talk]]''</sup> at
| |||